NAPIGEN, INC.


Associated tags: Mitochondrion, Climate change, Animal, Plant, Agriculture, Biotechnology, Chloroplast, DNA, Cell, PeerJ, Vaccine, RNA, Organelle, NIH, RA, CRISPR, Gene editing, Chlamydomonas

Locations: DELAWARE, WILMINGTON, US, UNITED STATES

NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant

Retrieved on: 
Monday, March 11, 2024
SBIR, CRISPR, Biotechnology, Climate, Farmer, Patent, Plant, Cell, Business development, Small Business Innovation Research, Mitochondrion, Plastid, RNA, Genome, United, Intellectual property, Food security, Pollen, DNA

The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.

Key Points: 
  • The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.
  • The mitochondria, also known as the powerhouses of cells, are critical components of plant, fungal, algal, and animal cells.
  • It is the third SBIR grant the company has received since its founding in 2016.
  • NAPIGEN, Inc. expects to complete a Series A financing this year to advance partnerships with agricultural companies to bring products to market.

NAPIGEN Completes $7.85 Million Funding Round to Advance Its Mitochondrial and Chloroplast Gene Editing Technology

Retrieved on: 
Tuesday, July 12, 2022
Technology, Biotechnology, Mitochondrion, Animal, Gene editing, CRISPR, Agriculture, CEO, Plant, RA, GLOBE, NIH, PeerJ, Chloroplast, Cell, Organelle, RNA, DNA, Vaccine, Chlamydomonas

WILMINGTON, Del., July 12, 2022 (GLOBE NEWSWIRE) -- NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round.

Key Points: 
  • WILMINGTON, Del., July 12, 2022 (GLOBE NEWSWIRE) -- NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round.
  • NAPIGEN will use the funding to apply its mitochondrial gene editing technology for hybrid seed production in wheat and rice.
  • More recently, NAPIGEN has applied its technology to gene editing of plant mitochondrial DNA in rice.
  • NAPIGEN also has received funding from the United Mitochondrial Disease Foundation and the NIH-SBIR program to apply its technology to gene editing of human mitochondrial DNA.

NAPIGEN Publication Provides Proof of Concept of its Technology for Editing Cytoplasmic Genome (Mitochondrial and Chloroplast Genome)

Retrieved on: 
Tuesday, January 28, 2020
Branches of biology, Biology, Genetic engineering, Immune system, Enzymes, Cas9, Genome editing, Guide RNA, PeerJ, Mitochondrion

Scientists at NAPIGEN published their study, Cas9/gRNA-mediated genome editing of yeast mitochondria and Chlamydomonas chloroplasts, in January in the open-access, peer-reviewed journal PeerJ-Life and Environment (PeerJ 8:e8362 https://doi.org/10.7717/peerj.8362 ).

Key Points: 
  • Scientists at NAPIGEN published their study, Cas9/gRNA-mediated genome editing of yeast mitochondria and Chlamydomonas chloroplasts, in January in the open-access, peer-reviewed journal PeerJ-Life and Environment (PeerJ 8:e8362 https://doi.org/10.7717/peerj.8362 ).
  • Our approach has broad applications in agriculture, industrial biotechnology, human healthcare, said Dr. Hajime Sakai, co-founder, president, and CEO of NAPIGEN.
  • The first cassette was for the expression of Cas9 and the other cassette was for the expression of guide RNAs.
  • The company is also extending the technology in yeast mitochondria and exploring mechanisms to pursue both industrial and mammalian applications.